ArticleCureus2025
Quality of Life Outcomes After Fundoplication-Augmented One-Anastomosis Gastric Bypass: A Randomized Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gastroesophageal reflux disease (GERD) frequently persists despite weight reduction, thereby diminishing anticipated improvements in quality of life following bariatric surgery. While one-anastomosis gastric bypass (OAGB) is metabolically effective, it may not completely manage reflux symptoms. This study assessed whether the incorporation of a modified fundoplication could enhance symptom control and health-related quality of life (HRQoL) compared with OAGB alone. Methods A prospective randomized comparative study was conducted involving 60 patients diagnosed with obesity and GERD. Participants were randomly allocated into two groups for a follow-up period of two years: Group A underwent OAGB only, and Group B received OAGB with modified fundoplication. Outcomes were evaluated based on preoperative and postoperative upper GI and manometry findings, as well as postoperative GERD-Health-Related Quality of Life (GERD-HRQL) scores. Results In comparison to OAGB alone, fundoplication demonstrated superior symptom control (Visick 2.10 ± 0.71 vs. 3.57 ± 0.73; p = 0.001) and resulted in a shorter duration of PPI use (2.43 ± 0.62 vs. 3.13 ± 0.68 months; p = 0.001). The GERD-HRQL scores showed significant improvement following fundoplication at six months (48.33 ± 7.91 to 31.57 ± 3.90; p < 0.001), and this improvement was sustained up to 24 months, whereas the changes observed after OAGB alone were not statistically significant. At the 24-month mark, endoscopic evaluation revealed an intact wrap with no evidence of GERD, and manometry confirmed restoration of LES function. Conclusions Compared with OAGB alone, the combination of OAGB with modified fundoplication offers a distinct advantage in terms of quality of life, as evidenced by improved symptom scores, decreased reliance on proton pump inhibitors, and enhanced endoscopic and manometric control of reflux. This integrated approach represents a viable strategy for optimizing the HRQoL of patients with obesity and GERD. However, validation through larger multicenter studies with extended follow-up periods and pH impedance monitoring is necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.